Targeted Oncology2h
Beckermann and Participants Discuss Second-Line ccRCC Options
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...
Managed Healthcare Executive3h
FDA Adds Boxed Warning to MS Drug Copaxone
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated ...
Managed Healthcare Executive4h
BLA Accepted for Melanoma Combination Therapy, RP1 and Nivolumab
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.
The Pharma Letter10h
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
RS-NEWS15h
How Skin Cancer Treatments Are Being Transformed for Better Outcomes
The future of skin cancer treatment looks even more promising. Advances in artificial intelligence (AI) are revolutionizing ...
ImmunityBio: Despite Anktiva's Clinical Promise, This Remains A Difficult Investment
ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.